局晚期头颈鳞癌辅助化疗的研究现状
Research Status of Adjuvant Chemotherapy for Advanced Head and Neck Squamous Cell Carcinoma
摘要: 局晚期头颈部鳞癌(head and neck squamous cell carcinoma)是常见的恶性肿瘤,有超过一半的患者被发现时处于局部晚期,生存率不高,主要治疗手段以手术及放疗为主,但全身化疗也越来越多地与放疗和手术相结合,比如辅助化疗、诱导化疗及同步化疗。本文就局部晚期头颈部鳞癌辅助化疗的研究现状做一综述,旨在为临床工作中是否应对局晚期头颈部鳞癌患者行辅助化疗提供参考。
Abstract: Advanced head and neck squamous cell carcinoma is a common malignant tumor, more than half of the patients are found in the local advanced stage, the survival rate is not high, the main treatment methods are mainly surgery and radiotherapy, but systemic chemotherapy is also increasingly combined with radiotherapy and surgery, such as adjuvant chemotherapy, induction chemotherapy and synchronous chemotherapy. This article reviews the current research status of adjuvant chemotherapy for locally advanced head and neck squamous cell carcinoma, aiming to provide reference for whether adjuvant chemotherapy should be performed in clinical work for patients with locally advanced head and neck squamous cell carcinoma.
文章引用:陈丽, 张涛. 局晚期头颈鳞癌辅助化疗的研究现状[J]. 临床医学进展, 2024, 14(5): 260-265. https://doi.org/10.12677/acm.2024.1451422

参考文献

[1] Chow, L.Q.M. (2020) Head and Neck Cancer. The New England Journal of Medicine, 382, 60-72. [Google Scholar] [CrossRef
[2] Baxi, S.S., Pinheiro, L.C., Patil, S.M., et al. (2014) Causes of Death in Long-Term Survivors of Head and Neck Cancer. Cancer, 120, 1507-1513. [Google Scholar] [CrossRef] [PubMed]
[3] Pignon, J.P., Bourhis, J., Domenge, C., et al. (2000) Chemotherapy Added to Locoregional Treatment for Head and Neck Squamous-Cell Carcinoma: Three Meta-Analyses of Updated Individual Data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. The Lancet, 355, 949-955. [Google Scholar] [CrossRef
[4] Pignon, J.P., le Maître, A., Maillard, E., et al. (2009) Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 93 Randomised Trials and 17,346 Patients. Radiotherapy and Oncology, 92, 4-14. [Google Scholar] [CrossRef] [PubMed]
[5] Wendt, T.G., Grabenbauer, G.G., Rödel, C.M., et al. (1998) Simultaneous Radiochemotherapy versus Radiotherapy Alone in Advanced Head and Neck Cancer: A Randomized Multicenter Study. Journal of Clinical Oncology, 16, 1318-1324. [Google Scholar] [CrossRef
[6] Bernier, J., Domenge, C., Ozsahin, M., et al. (2004) Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. The New England Journal of Medicine, 350, 1945-1952. [Google Scholar] [CrossRef
[7] Cooper, J.S., Zhang, Q., Pajak, T.F., et al. (2012) Long-Term Follow-Up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology, Biology, Physics, 84, 1198-1205. [Google Scholar] [CrossRef] [PubMed]
[8] Cooper, J.S., Pajak, T.F., Forastiere, A.A., et al. (2004) Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. The New England Journal of Medicine, 350, 1937-1944. [Google Scholar] [CrossRef
[9] Laramore, G.E., Scott, C.B., Al-Sarraf, M., et al. (1992) Adjuvant Chemotherapy for Resectable Squamous Cell Carcinomas of the Head and Neck: Report on Intergroup Study 0034. International Journal of Radiation Oncology, Biology, Physics, 23, 705-713. [Google Scholar] [CrossRef
[10] Caudell, J.J., Gillison, M.L., Maghami, E., et al. (2022) NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. Journal of the National Comprehensive Cancer Network, 20, 224-234. [Google Scholar] [CrossRef] [PubMed]
[11] Lacas, B., Carmel, A., Landais, C., et al. (2021) Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 107 Randomized Trials and 19,805 Patients, on Behalf of MACH-NC Group. Radiotherapy and Oncology, 156, 281-293. [Google Scholar] [CrossRef] [PubMed]
[12] Holoye, P.Y., Grossman, T.W., Toohill, R.J., et al. (1985) Randomized Study of Adjuvant Chemotherapy for Head and Neck Cancer. Otolaryngology-Head and Neck Surgery, 93, 712-717. [Google Scholar] [CrossRef] [PubMed]
[13] Kun, L.E., Toohill, R.J., Holoye, P.Y., et al. (1986) A Randomized Study of Adjuvant Chemotherapy for Cancer of the Upper Aerodigestive Tract. International Journal of Radiation Oncology, Biology, Physics, 12, 173-178. [Google Scholar] [CrossRef] [PubMed]
[14] Taylor 4th, S.G., Applebaum, E., Showel, J.L., et al. (1985) A Randomized Trial of Adjuvant Chemotherapy in Head and Neck Cancer. Journal of Clinical Oncology, 3, 672-679. [Google Scholar] [CrossRef
[15] Ang, K.K., Trotti, A., Brown, B.W., et al. (2001) Randomized Trial Addressing Risk Features and Time Factors of Surgery Plus Radiotherapy in Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology, Biology, Physics, 51, 571-578. [Google Scholar] [CrossRef
[16] Bernier, J., Cooper, J.S., Pajak, T.F., et al. (2005) Defining Risk Levels in Locally Advanced Head and Neck Cancers: A Comparative Analysis of Concurrent Postoperative Radiation Plus Chemotherapy Trials of the EORTC (#22931) and RTOG (# 9501). Head & Neck, 27, 843-850. [Google Scholar] [CrossRef] [PubMed]
[17] Rosenthal, D.I., Liu, L., Lee, J.H., et al. (2002) Importance of the Treatment Package Time in Surgery and Postoperative Radiation Therapy for Squamous Carcinoma of the Head and Neck. Head & Neck, 24, 115-126. [Google Scholar] [CrossRef] [PubMed]
[18] Cooper, J.S., Pajak, T.F., Forastiere, A., et al. (1998) Precisely Defining High-Risk Operable Head and Neck Tumors Based on RTOG #85-03 and #88-24: Targets for Postoperative Radiochemotherapy? Head & Neck, 20, 588-594. [Google Scholar] [CrossRef
[19] Dewit, L. (1987) Combined Treatment of Radiation and Cisdiamminedichloroplatinum (II): A Review of Experimental and Clinical Data. International Journal of Radiation Oncology, Biology, Physics, 13, 403-426. [Google Scholar] [CrossRef] [PubMed]
[20] Bachaud, J.M., Cohen-Jonathan, E., Alzieu, C., et al. (1996) Combined Postoperative Radiotherapy and Weekly Cisplatin Infusion for Locally Advanced Head and Neck Carcinoma: Final Report of a Randomized Trial. International Journal of Radiation Oncology, Biology, Physics, 36, 999-1004. [Google Scholar] [CrossRef
[21] Johnson, J.T., Myers, E.N., Schramm Jr., V.L., et al. (1987) Adjuvant Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 5, 456-458. [Google Scholar] [CrossRef
[22] Tobias, J.S., Monson, K., Gupta, N., et al. (2010) Chemoradiotherapy for Locally Advanced Head and Neck Cancer: 10-Year Follow-Up of the UK Head and Neck (UKHAN1) Trial. The Lancet Oncology, 11, 66-74. [Google Scholar] [CrossRef
[23] (1987) Adjuvant Chemotherapy for Advanced Head and Neck Squamous Carcinoma. Final Report of the Head and Neck Contracts Program. Cancer, 60, 301-311. [Google Scholar] [CrossRef
[24] Jacobs, C. and Makuch, R. (1990) Efficacy of Adjuvant Chemotherapy for Patients with Resectable Head and Neck Cancer: A Subset Analysis of the Head and Neck Contracts Program. Journal of Clinical Oncology, 8, 838-847. [Google Scholar] [CrossRef
[25] Hitt, R., López-Pousa, A., Martínez-Trufero, J., et al. (2005) Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 23, 8636-8645. [Google Scholar] [CrossRef
[26] Kubota, A., Nakatani, E., Tsukahara, K., et al. (2018) Adjuvant Chemotherapy with S-1 after Curative Chemoradiotherapy in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: Reanalysis of the ACTS-HNC Study. PLOS ONE, 13, e0198391. [Google Scholar] [CrossRef] [PubMed]
[27] Tsukahara, K., Kubota, A., Hasegawa, Y., et al. (2015) Randomized Phase III Trial of Adjuvant Chemotherapy with S-1 after Curative Treatment in Patients with Squamous-Cell Carcinoma of the Head and Neck (ACTS-HNC). PLOS ONE, 10, e0116965. [Google Scholar] [CrossRef] [PubMed]
[28] Posner, M.R., Hershock, D.M., Blajman, C.R., et al. (2007) Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. The New England Journal of Medicine, 357, 1705-1715. [Google Scholar] [CrossRef